E-mail us: service@prospectnews.com Or call: 212 374 2800
Bank Loans - CLOs - Convertibles - Distressed Debt - Emerging Markets
Green Finance - High Yield - Investment Grade - Liability Management
Preferreds - Private Placements - Structured Products
 
Published on 12/7/2017 in the Prospect News Investment Grade Daily.

S&P assigns AA to Pfizer notes

S&P said it assigned an AA issue-level rating to Pfizer Inc.'s offering of senior unsecured sterling-denominated notes due 2043.

The offering is part of the company's tender offer for cash or exchange targeting its £1.5 billion 6.5% senior unsecured notes due June 2038.

The agency said the transaction does not materially affect the company from a net leverage perspective.

The AA long-term corporate credit rating reflects the company's diverse portfolio of high-margin pharmaceuticals, with strengths in neurology, oncology and vaccines, S&P said.


© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.